ALT Sex- and Cycle-Related Differences: Normal Range, Optimal Levels, and What Your Result Really Means

What ALT Measures and Why the Standard Cutoff Is Too High

ALT is a cytosolic enzyme released when hepatocytes are damaged or dying. It is more liver-specific than AST, making it the first-line biochemical marker for hepatocellular injury, metabolic-associated steatotic liver disease (MASLD), drug-induced liver injury (DILI), and viral hepatitis monitoring.

The problem is that most clinical laboratories still use an upper limit of normal (ULN) between 40 and 56 U/L, a threshold derived decades ago from blood-bank donor populations that were skewed male, often overweight, and not screened for subclinical liver disease. A landmark reanalysis by Prati et al. (2002) in the New England Journal of Medicine, drawing on 3,927 healthy Italian blood donors, proposed sex-specific ULNs of 30 U/L for men and 19 U/L for women [1]. That paper reframed how hepatologists think about "normal."

The NHANES Evidence for Lower Thresholds

Data from the U.S. National Health and Nutrition Examination Survey (NHANES) reinforce this point. An analysis of NHANES III and continuous NHANES (N > 15,000 adults free of liver disease, heavy alcohol use, and obesity) placed the 95th-percentile ALT at 29 U/L for men and 22 U/L for women [2]. When the same dataset was restricted to metabolically healthy, non-obese, non-drinking adults, the 97.5th percentile fell to roughly 25 U/L in men and 19 U/L in women.

These numbers matter because a woman with ALT of 38 U/L looks "normal" on a standard report but sits nearly twice her evidence-based ULN.

Why the Gap Between Sexes Exists

Estrogen upregulates hepatic lipid export via VLDL secretion and maintains lower hepatic fat content on average. Women also carry less skeletal muscle mass per kilogram of body weight, which reduces baseline ALT production from non-hepatic sources. The net result: healthy premenopausal women run ALT roughly 30 to 40% lower than age-matched men at the same body-mass index [3].

ALT Across the Menstrual Cycle

The menstrual cycle produces measurable fluctuations in ALT, though the magnitude is modest. Several prospective studies tracking ALT across 28-day cycles found values 8 to 15% lower in the mid-luteal phase (days 18 to 24) compared with the early follicular phase (days 2 to 5) [4]. Progesterone, which peaks in the luteal phase, may suppress hepatic ALT synthesis or accelerate its clearance, though the mechanism has not been pinned down in humans.

Clinical Implications for Cycle-Aware Testing

A single ALT drawn in the luteal phase in a woman with borderline hepatic steatosis could fall within the reference range and delay diagnosis. Conversely, a follicular-phase draw might produce a value that triggers unnecessary workup.

For any woman with a borderline ALT (19 to 35 U/L on a sensitive threshold), the practical step is to retest on day 5 to 8 of the cycle (early follicular, after menstruation begins) to get a cycle-phase-stable reading. Repeat tests should use the same phase when possible.

The HealthRX clinical team uses a three-point protocol for cycle-aware ALT interpretation:

1. Draw on cycle day 5 to 8 (early follicular) whenever scheduling permits.
2. If the result is 19 to 35 U/L, confirm with a second draw in the same cycle phase 6 to 8 weeks later before initiating workup.
3. Document cycle day on the lab requisition so the reviewing clinician can contextualize the value.

How Estrogen Affects ALT: OCP, HRT, and Gender-Affirming Hormone Therapy

Exogenous estrogen lowers ALT in most clinical scenarios, but the route of delivery and dose matter.

Combined Oral Contraceptives

Combined oral contraceptive pills (COCPs) containing ethinyl estradiol (20 to 35 mcg) are associated with ALT reductions of roughly 5 to 12% in observational studies [5]. This estrogen-driven suppression means a woman starting a COCP will often show a small, spurious ALT decrease on her next panel. It does not reflect improved liver health. It reflects pharmacologic suppression of the enzyme.

The flip side: high-dose estrogen preparations (older 50 mcg pills or estrogen used in fertility protocols) carry a small risk of cholestasis and ALT elevation, particularly in women with a genetic susceptibility to estrogen-induced cholestasis (variants in ABCB4 or ABCB11) [6].

Menopausal Hormone Therapy

Transdermal estradiol (0.05 to 0.1 mg/day patches) in postmenopausal women does not significantly change ALT in most cohorts. Oral estradiol (1 to 2 mg/day) shows modest ALT reductions similar to COCP data, likely because first-pass hepatic metabolism exposes the liver to higher estrogen concentrations [7].

The ELITE trial (N=643, mean age 55 years, median follow-up 4.8 years) did not specifically report ALT as a primary endpoint, but secondary metabolic data were consistent with a mild hepatoprotective effect of oral 17-beta-estradiol compared with placebo [8].

Estrogen in Gender-Affirming Hormone Therapy (GAHT)

Transgender women (assigned male at birth) starting estradiol typically see ALT fall toward female-range values within 3 to 6 months. A prospective cohort study by Wierckx et al. Found that ALT dropped a mean of 18% over 12 months in transfeminine individuals on estradiol valerate 2 to 6 mg/day [9]. This shift reflects both the direct hepatic effect of estrogen and the partial redistribution of body fat away from visceral depots.

How Testosterone Affects ALT: TRT and Masculinizing GAHT

Testosterone raises ALT. That is the consistent finding across testosterone-replacement therapy (TRT) trials in hypogonadal men and masculinizing GAHT studies in transgender men.

Testosterone Replacement Therapy in Men

In the Testosterone Trials (TTrials, N=790 men, mean age 72, testosterone gel 1% titrated to mid-normal range), ALT rose a mean of 12% from baseline at 12 months. Values remained within the standard lab ULN for most participants, but when compared against the sex-specific threshold of 29 to 33 U/L, a meaningful subset crossed into the elevated zone [10].

Higher doses and injectable formulations (testosterone cypionate 100 to 200 mg IM every 1 to 2 weeks) show larger ALT increases than transdermal gels. A 2021 retrospective review in JAMA Internal Medicine found that men on injectable testosterone were 2.3 times more likely to have ALT above 40 U/L compared with men on transdermal formulations, even after adjusting for dose and BMI [11].

The Endocrine Society's 2018 guideline on testosterone therapy states: "Liver function tests should be obtained at baseline and at 3 and 6 months after starting testosterone therapy, and annually thereafter" [12]. This reflects the recognized ALT-raising effect of the drug.

Testosterone in Masculinizing GAHT

Transgender men starting testosterone (typically testosterone cypionate or enanthate 50 to 100 mg IM weekly, or transdermal testosterone 1.62% gel) show ALT increases of 15 to 30% within the first 3 months, with values plateauing by 6 months in most individuals [13]. The increase is dose-dependent and larger in those who start with lower baseline ALT, as expected.

Because transgender men transition from a female-range ALT baseline (mean roughly 15 to 18 U/L) toward a male-range baseline (mean roughly 22 to 26 U/L), a post-testosterone ALT of 30 U/L is not automatically pathological. It sits near the evidence-based male ULN. The error clinicians make is applying the standard 40 to 56 U/L cutoff and calling it "fine," when it actually represents a >100% increase from the individual's pre-treatment baseline.

ALT in Pregnancy: When "Normal" Drops, a Rise Is a Warning Sign

Pregnancy normally suppresses ALT. Hemodilution, altered hepatic blood flow, and placental production of competing enzymes all contribute to a physiologic drop of roughly 15 to 25% during the first and second trimesters [14].

Gestational Thresholds

An ALT above 30 U/L in any trimester should prompt clinical attention, even if it falls within standard lab ranges. The following conditions raise ALT in pregnancy and require timely differentiation:

• Intrahepatic cholestasis of pregnancy (ICP): ALT typically 2 to 10x ULN; bile acids >10 micromol/L confirm diagnosis.
• HELLP syndrome: ALT elevation accompanies low platelets and hemolysis; AST often rises faster than ALT.
• Acute fatty liver of pregnancy (AFLP): ALT rises modestly (100 to 500 U/L) but encephalopathy and coagulopathy signal severity.
• Pre-existing MASLD unmasked by pregnancy: Baseline metabolic liver disease may not produce obvious ALT elevation until the metabolic demands of pregnancy stress an already-reduced hepatic reserve.

The American College of Obstetricians and Gynecologists (ACOG) advises liver function testing as part of the diagnostic workup for any pregnant patient with right upper-quadrant pain, unexplained nausea after 20 weeks, or signs of preeclampsia [15].

The Optimal ALT Range: Longevity Medicine and MASLD Screening Perspectives

Standard reference ranges define "not sick." The optimal range defines "lowest long-term risk."

Mortality and Cancer Data

A large Korean prospective cohort (N=510,441 adults, median follow-up 9.9 years) published in Gut (2021) found that all-cause mortality risk was lowest in men with ALT 10 to 20 U/L and women with ALT 7 to 15 U/L. Risk increased in a J-shaped curve: very low ALT (<7 U/L) correlated with malnutrition-related mortality, and ALT above 25 U/L (women) or 35 U/L (men) correlated with cancer and cardiovascular mortality even within the standard "normal" range [16].

MASLD Screening Cutoffs

The American Association for the Study of Liver Diseases (AASLD) 2023 guidance on MASLD recommends considering further workup (hepatic steatosis score, FIB-4, or ultrasound) when ALT exceeds 19 U/L in women or 30 U/L in men, regardless of whether the result falls within the local lab's ULN [17].

The AASLD document states: "Sex-specific ALT thresholds better identify individuals with hepatic steatosis and early fibrosis who would be missed by traditional upper limits of normal."

Practical Optimal Targets for HealthRX Patients

Based on the NHANES healthy-reference data, the Korean mortality curve, and AASLD guidance, the HealthRX medical team uses the following targets:

| Population | Target ALT (U/L) | Action Threshold (U/L) | |---|---|---| | Premenopausal women (no exogenous hormones) | 7 to 19 | >25 | | Postmenopausal women (off HRT) | 7 to 22 | >25 | | Women on oral estrogen (COCP or HRT) | 7 to 20 | >28 | | Men (no TRT) | 10 to 29 | >35 | | Men on TRT | 10 to 33 | >40 | | Transgender women (on estradiol >6 months) | 7 to 22 | >28 | | Transgender men (on testosterone >6 months) | 10 to 33 | >40 |

ALT and Anabolic / Performance-Enhancing Compounds

Supraphysiologic androgen use (anabolic-androgenic steroids, AAS) produces ALT elevations well outside any optimal range. Oral 17-alpha-alkylated androgens (oxymetholone, stanozolol, oxandrolone) are hepatotoxic; ALT values of 200 to 1,000 U/L are documented. Injectable testosterone at bodybuilding doses (300 to 1,000 mg/week) raises ALT more modestly, often to 60 to 120 U/L, but also elevates ALT from skeletal muscle breakdown rather than pure hepatocellular injury [18].

The AST/ALT ratio helps distinguish. A ratio >2:1 in an AAS user suggests muscle-source aminotransferase release more than hepatocellular damage. Adding creatine kinase (CK) to the panel clarifies the picture: CK >1,000 U/L with proportional AST/ALT elevation points to muscle, not liver.

How to Interpret Your ALT in the Context of Hormonal Therapy

A single ALT value without context is almost uninterpretable. The following factors must be recorded alongside every result:

• Sex and gender (to apply the correct reference range)
• Cycle day (for menstruating individuals)
• Current hormonal medications and doses (estrogen, progesterone, testosterone, SERM, aromatase inhibitor)
• Duration of current hormone regimen (ALT is not at steady state for the first 3 months)
• Alcohol intake in the prior 72 hours (even 2 to 3 drinks raise ALT transiently)
• Recent intense exercise (resistance training 24 to 48 hours prior can raise ALT 20 to 40% via muscle release)
• Current medications (statins, metformin, amiodarone, valproate, and dozens of others alter ALT)
• BMI and waist circumference (visceral adiposity is the strongest modifiable driver of elevated ALT in the general population)

The 6-Week Rule for Hormonal Therapy Changes

Any change in hormonal therapy (new medication, dose increase, formulation switch) should be followed by an ALT recheck at 6 to 8 weeks and again at 3 months. If ALT rises more than 50% from the pre-treatment baseline and exceeds the sex- and therapy-specific action threshold in the table above, the prescribing clinician should be notified before the next scheduled visit.

MASLD, Insulin Resistance, and ALT: The Metabolic Driver

Hormonal status shapes ALT, but insulin resistance is the dominant driver of persistently elevated ALT in most outpatient populations. Visceral fat generates free fatty acids that overwhelm hepatic beta-oxidation, producing intrahepatic triglyceride accumulation and hepatocellular stress.

In the PREDIMED-Plus trial (N=6,874 adults with metabolic syndrome, mean follow-up 3 years), intensive lifestyle intervention reduced ALT by a mean of 8.4 U/L in participants whose waist circumference dropped by at least 5 cm, independent of weight loss magnitude [19]. This finding underscores that waist reduction, not simply weight loss, drives hepatic ALT improvement.

For patients on GLP-1 receptor agonists: semaglutide 2.4 mg/week (as studied in the NASH trial, N=320) reduced liver fat content by 59% relative to placebo and produced mean ALT reductions of 18 U/L at 72 weeks, P<0.001 [20]. ALT monitoring every 3 months is a practical way to track hepatic response to GLP-1 therapy.